Drug Approval | April 15, 2022
Lupin receives approval from USFDA for Desvenlafaxine extended-release tablets 25 mg
The product will be manufactured at Lupin’s facility in Goa, India
The product will be manufactured at Lupin’s facility in Goa, India
This product is indicated for the short-term treatment of a breathing problem (apnea) in premature infants
Lidocaine and Prilocaine Cream USP, 2.5%/2.5% has an estimated market size of US $ 29 million for twelve months ending Dec. 2021 according to IQVIA
The tentatively approved ANDA is therapeutically equivalent to the reference listed drug product (RLD) Pradaxa Capsules of Boehringer lngelheim
All intellectual-property disputes related to the market entry of Alvotech’s AVT02 (adalimumab) in the U.S. and Europe are now resolved
Aveir VR is specifically designed to be retrieved when therapy needs to evolve or the device needs to be replaced
The product will be manufactured at Lupin’s facility in Goa, India
Data to establish the safety profile and human dose of vaccine candidate
Data published in the prestigious journal ACS Central Science of the American Chemical Society
The tablets are indicated for the treatment of partial-onset seizures in patients 4 years of age and older
Subscribe To Our Newsletter & Stay Updated
